News
AEON
1.500
-5.06%
-0.080
AEON Biopharma Halts Migraine Study and Evaluates Strategy
TipRanks · 12h ago
AEON Biopharma Price Target Cut to $6.00/Share From $18.00 by HC Wainwright & Co.
Dow Jones · 1d ago
AEON Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $6
Benzinga · 1d ago
Analysts Are Bullish on These Healthcare Stocks: AEON Biopharma (AEON), Palatin Technologies (PTN)
TipRanks · 1d ago
AEON Biopharma, Inc. GAAP EPS of -$3.17
Seeking Alpha · 1d ago
AEON Stock Earnings: AEON Biopharma Misses EPS for Q1 2024
AEON Biopharma reported earnings per share of -$ for the first quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -39 cents. AEON biopharma is a biopharmaceutical company.
Investorplace · 2d ago
AEON Biopharma, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 2d ago
AEON Biopharma Q1 2024 Adj EPS $(3.17) Misses $(0.31) Estimate
Benzinga · 2d ago
Press Release: AEON Biopharma Reports First -2-
Three months ended March 31, 2016, AEON had a net loss of $1.7 million. The Company has a total of $9.1 million in cash and short-term investments. The company has no debt and no long-term liabilities. The Company's stockholders' deficit for the first quarter of 2016 was $2.2 million. The company expects to close out the year with a positive free cash flow.
Dow Jones · 2d ago
Weekly Report: what happened at AEON last week (0506-0510)?
Weekly Report · 3d ago
AEON Biopharma Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 05/06 10:54
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
Benzinga · 05/06 10:44
Weekly Report: what happened at AEON last week (0429-0503)?
Weekly Report · 05/06 10:21
Maintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 Setback
TipRanks · 05/06 10:18
Health Care Sector Update for 05/03/2024: AEON, MODV, AMGN, TWST
NASDAQ · 05/03 19:55
S&P 500 Rises Over 1%; Hershey Earnings Top Views
U.S. Stocks traded higher toward the end of trading on Friday. The Dow traded up 1.27% and the S&P 500 gained more than 1%. Information technology shares rose by 3.3% after Hershey Company reported better-than-expected first-quarter results. Asian markets closed mixed on Friday; European shares were higher.
Benzinga · 05/03 18:30
Newly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday - Read Here Why
AEON Biopharma says ABP-450 did not meet the primary endpoint of a Phase 2 migraine trial. The company says the reduction in monthly migraine days in the placebo arm was much higher than expected. The preliminary top-line results of the study did not achieve statistical significance.
Benzinga · 05/03 17:11
Nasdaq Surges 2%; Apple Posts Upbeat Results
U.S. Stocks traded higher midway through trading on Friday. The Dow traded up 1.16% and the Nasdaq Composite gained 2%. Apple, Inc. Reported better-than-expected results for its second quarter. Information technology shares rose by 3.2% on Friday; energy shares fell by 0.3%. Euro zone European shares were higher today.
Benzinga · 05/03 16:49
12 Health Care Stocks Moving In Friday's Intraday Session
Eliem Therapeutics (NASDAQ:ELYM) shares moved upwards by 32.8% to $11.14 during Friday's regular session. Ardelyx shares rose 26.5% and Twist Bioscience stock increased by 25.81% in the last day. The company's, Q1 earnings came out yesterday. Mobile-health Network shares decreased by 73.8%.
Benzinga · 05/03 16:31
More
Webull provides a variety of real-time AEON stock news. You can receive the latest news about Aeon Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About AEON
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.